# Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

> **NCT07402473** · PHASE2 · RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 50 (estimated)

## Conditions studied

- HER2-positive Early-stage Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Docetaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT07402473
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-26
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07402473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07402473, "Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07402473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*